Good afternoon, everyone, and welcome to our fourth quarter 2025 earnings call. Bob Bradway will lead the call today and be ...
The Trump administration is preparing to launch TrumpRx.com, an initiative aimed at lowering drug costs by aggregating direct-to-consumer access to branded prescription medications at discounted cash ...
Amgen Inc. (NASDAQ:AMGN) Q4 2025 Earnings Call Transcript February 3, 2026 Amgen Inc. beats earnings expectations. Reported ...
StockStory.org on MSN
AMGN Q4 deep dive: Product portfolio expansion and pipeline progress drive outlook
Biotech company Amgen (NASDAQ:AMGN) in Q4 CY2025, with sales up 8.6% year on year to $9.87 billion. The company’s full-year ...
During the first half of 2025, Wegovy and Zepbound, two weight loss drugs, ranked among the top 10 best-selling medicines ...
By Deena Beasley Feb 3 (Reuters) - Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall ...
Looking ahead, Amgen issued 2026 guidance with revenue projected between $37.0 billion and $38.4 billion, compared to the consensus estimate of $37.1 billion. The company expects adjusted EPS of ...
Amgen Inc. reports fourth-quarter earnings today after the bell, putting the spotlight on how the $185.6 billion biotechnology giant plans to navigate a year marked by significant biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results